Strong YoY growth masks QoQ PAT collapse; Africa expansion bullish but unquantified
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Maintained Q1 guidance pattern (no numeric targets); YoY metrics hit but QoQ deterioration not addressed on call.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered solid YoY growth (revenue +38%, PAT +44%) backed by Poultry Healthcare momentum and improved product mix, but sequential PAT collapse of 78.7% despite 26.8% revenue growth signals margin deterioration that management did not disclose or explain. Africa expansion and biologicals pipeline offer multi-year upside but remain unquantified; near-term execution risk around Animal Health segment recovery and regulatory hurdles.
₹97.9 Cr
Revenue · +38% YoY₹20.6 Cr
Reported PAT · +44% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Revenue grew 38% YoY in Q2, PAT up 44%
METDelivered: revenue +38% YoY, PAT +44% YoY. Claims exactly match reported results.
Poultry Healthcare grew 27% in Q2 and 37% in H1
METClaims made but segment breakdown not separately verified against consolidated ₹97.9 Cr (Q2). Appears consistent with ₹70+ Cr range implied.
Margin maintained at 78% gross profit, 35% EBITDA
MixedDelivered: OPM 33.8%, NPM 20.8%. EBITDA/gross claims not independently validated from P&L.
Momentum from Q1 to Q2 maintained, 'strong base' set for H2
MISSQoQ revenue +26.8% but PAT collapsed -78.7% QoQ despite revenue growth. Profitability momentum severely broken.
No foreign entity subsidiaries making losses, consolidated profit up 40%
OVERSTATEDStated profit growth 44% YoY, not 40%. Minor discrepancy in quoted figure.
Very bullish on Africa, entered multiple export markets across Africa/Middle East/Asia
OVERSTATEDNo revenue/order book disclosed for Africa. Injecting $1M loan but business still pre-scale. Bullish sentiment unsupported by numbers.
Earnings quality
What changed since the last call
Margin outlook hedged vs Q1
DowngradeQ1 call: implied confidence in 35% EBITDA sustainability. Q2 results: EBITDA margin claimed at 35% but NPM only 20.8% vs implied 22-24% in prior year. Operating leverage not flowing through.
Export ambition elevated
UpgradeQ1 call: 10% of India revenue from exports. Q2 call: 'ratio would have definitely improved' but no number given. FY27 export contribution expected higher than FY26's 10%.
Africa investment accelerated
NewQ1 call: losses in Africa, focus on sustainability. Q2 call: injecting $1M loan, 'extremely bullish', entering Africa/ME/Asia markets. Tone shifted from defensive to offensive.
Regulatory headwinds acknowledged
NewQ2 call: 'regulatory requirements...increasingly rigorous, particularly around documentation, compliance and trial requirements.' Not material in Q2 but flagged as future capex pressure.
The Q&A
Analysts pressed hard on H9N2 sales breakdown, Africa execution details, and R&D asset capitalization. Management held firm on refusing H9N2 specifics ('won't be in position to give detailed volume led'), deflected Africa margin impact, and clarified R&D assets are development expenses. Tone was professional but protective on competitive sensitivity.
Export growth trajectory — Ankit, Zen Nivesh Advisors
PartialFY26 India exports ~10%; FY27 ratio would have definitely improved given new export opportunities embarked upon. No specific percentage given.
Africa intercompany loan — Ankit, Zen Nivesh Advisors
PartialLoan is 100% owned subsidiary requirement for fortification. Yes, will translate to improved Africa performance and multi-market entry. Bullish but non-numeric.
Capacity utilization and capex — Ankit, Zen Nivesh Advisors
PartialApproximately 65% utilization. Regulatory requirements may drive some capex, still in planning phase, will relook infrastructure from technology/compliance angles. No concrete number.
R&D asset capitalization — Madhur Rathi, Counter Cyclical Investments
AnsweredThese are R&D and licensing expenses for product development, capitalized till commercialization. All part of balance sheet, not separate BSL-3 depreciation.
Foreign subsidiary losses — Madhur Rathi, Counter Cyclical Investments
AnsweredNo specific separate entity making losses. Consolidated profit up 40%.
Poultry Healthcare product mix — Saurab, Paul Asset
DodgedPoultry vaccines are strength. Focus on institutional business penetration and customer engagement. H9N2 contributed but won't give detailed H9N2 volume or revenue split.
Animal Health tender pipeline — Madhur Rathi, Counter Cyclical Investments
PartialVery simple answer: yes, we want to maintain momentum. Both segments work differently, seasonalities differ. Strong base set, want to maintain.
Africa profitability roadmap — Manish Jain, GormalOne LLC
PartialFocus on ruminant vaccines in Africa, primarily producing there. Cannot be manufactured in India. Bullish on Africa but will not segment out Africa separately.
Guidance
No FY27 revenue target disclosed
LowManagement refuses specific targets, consistent with Q1 call. Growth from biologicals, Africa, poultry healthcare but no number attached.
EBITDA margin 35%, focus on sustained operational improvements
Medium35% EBITDA margin claimed for both Q2 and H1. OPM 33.8% in Q2 suggests 35% EBITDA is realistic mid-point, but margin trajectory is uncertain.
Capex for regulatory compliance and technology refresh TBD
LowRegulatory requirements for animal health products becoming 'increasingly rigorous'; may require incremental capex. No amount or timeline specified.
Risks the call surfaced
Profitability volatility
HighPAT fell 78.7% QoQ (revenue +26.8%) signaling cost spikes, working capital swing, or depreciation headwind not disclosed. Margin sustainability in doubt.
Regulatory compliance
MediumManagement flagged 'increasingly rigorous' regulatory requirements around documentation, compliance, and trials. Could delay product approvals and increase development capex.
Segment seasonality
MediumAnimal Healthcare H1 FY27 revenue 14% below prior year due to weak Q1 tender execution. Government procurement timings cause revenue lumpy-ness.
Africa execution risk
HighAfrica expansion described as 'extremely bullish' but unfunded until Q2 $1M injection; market entry across continent but no revenue/customer traction disclosed.
Product concentration
MediumPoultry Healthcare +27% Q2 driven partly by H9N2 vaccine but management refused to quantify H9N2 revenue share or repeat customer base.
Management
Score 7/10. Clear on strategy (biologicals, Africa, institutional reach) but evasive on numbers (H9N2 sales, Africa revenue, exact capex). Candid on regulatory challenges; transparent on losses. Delivered Q2 YoY targets (+38% rev, +44% PAT) but Q1 profitability was exceptional (accounting gain), masking organic trend. QoQ collapse unaddressed. Track record mixed.
1 · Q3 FY27
Animal Health tender execution momentum and H9N2 vaccine commercial traction (refused detail)
2 · By Nov 15 2026
Completion of ₹1M intercompany loan to Hester Africa for working capital and market development
3 · H2 FY27
Biologicals pipeline regulatory approvals (Brucella recombinant, LPAI vaccine); Africa ruminant vaccine commercialization
Africa expansion and biologicals pipeline offer multi-year upside but remain unquantified; near-term execution risk around Animal Health segment recovery and regulatory hurdles.
Informational and educational content only. Not investment advice.